Search - tctmd.com

Displaying 361 - 380 of 444

Sort: Relevancy | Date

News Industry News

OrbusNeich Launches World’s First Dual Therapy Stent That Addresses Challenges of Delayed Coronary Artery Healing Associated with Monotherapy Drug Eluting Stents

May 27, 2013

Presentation EuroPCR 2013

The Unplanned DAPT Discontinuation Patient: How Can I Make Informed Decisions?

Presenter: Sigmund Silber

May 22, 2013

News Industry News

CID releasesDemonstr8 randomised trialresults during Late Breaking Trials

May 22, 2013

News Industry News

CID SpA Sponsors a Major Symposium at EuroPCR 2013 on Thursday 23rd of May

May 17, 2013

News Daily News

TWENTE: Still Few Differences between ZES and EES at 2 Years

L.A. McKeown

May 03, 2013

News Daily News

TWENTE: Sigue habiendo Pequeñas Diferencias entre los SLZ y los SLE a los 2 Años

L.A. McKeown

May 03, 2013

Presentation

Clinical Outcome Following Discontinuation of DAPT After 12 months in Real-World Patients Treated with Second-Generation ZES and EES

Presenter: K. Tandjung

April 26, 2013

Presentation TCTAP 2013

The Future Is: New Antiplatelet Agents, Selective Platelet Function Testing, and Patient-Specific DAPT Duration

Presenter: Matthew J. Price

April 24, 2013

Presentation TCTAP 2013

Counterpoint: The Incremental Benefit Is Small and the Cost-Disadvantages of New DAPT Approaches Are Prohibitive

Presenter: Adnan Kastrati

April 24, 2013

News Daily News

Rivaroxaban Added to Dual Antiplatelet Therapy Cuts Stent Thrombosis in ACS Patients

Caitlin E. Cox

April 19, 2013

News Daily News

Zilver PTX 2-Year Results Published: Superior Safety, Efficacy vs. Angioplasty Sustained

April 12, 2013

News Daily News

Resultado de 2 Años del Zilver PTX Publicados: Seguridad y Eficacia Superiores frente a Angioplastia Sostenida

April 12, 2013

News Opinion Conversations in Cardiology

Conversations in Cardiology: Brief Question re: BMS-DES and DAPT

March 20, 2013

News Conference News ACC 2013

Aspirin Alone Just as Good as Dual Antiplatelet Therapy Beyond 12 Months

Jason Kahn

March 11, 2013

Presentation PCI Outcomes 2013

DAPT + Oral Anticoagulation: Indications and Risk Amelioration

Presenter: C. Michael Gibson

March 07, 2013

News Industry News

Medtronic Approved to Update Resolute Integrity Stent’s ‘CE’ Mark Labeling on Dual Antiplatelet Therapy

March 03, 2013

News Daily News

Ideal Duration of Dual Antiplatelet Therapy May Depend on Stent Type

Jason Kahn

January 22, 2013

News Daily News

TCTMD’s Top 10 Most Popular News Stories for 2012

Jason Kahn

January 02, 2013

News Industry News

Case Report: Use of OrbusNeich’s Genous™ Stent with Bivalirudin for Acute Coronary Syndrome Patients at Risk for Bleeding Due to Hematological Cancer

December 16, 2012

News Industry News

CID Spa releases the NEXT Study 24-months data on its Cre8™ DES at TCT 2012

December 10, 2012

Advertisement

OrbusNeich Launches World’s First Dual Therapy Stent That Addresses Challenges of Delayed Coronary Artery Healing Associated with Monotherapy Drug Eluting Stents

The Unplanned DAPT Discontinuation Patient: How Can I Make Informed Decisions?

CID releasesDemonstr8 randomised trialresults during Late Breaking Trials

CID SpA Sponsors a Major Symposium at EuroPCR 2013 on Thursday 23rd of May

TWENTE: Still Few Differences between ZES and EES at 2 Years

TWENTE: Sigue habiendo Pequeñas Diferencias entre los SLZ y los SLE a los 2 Años

Clinical Outcome Following Discontinuation of DAPT After 12 months in Real-World Patients Treated with Second-Generation ZES and EES

The Future Is: New Antiplatelet Agents, Selective Platelet Function Testing, and Patient-Specific DAPT Duration

Counterpoint: The Incremental Benefit Is Small and the Cost-Disadvantages of New DAPT Approaches Are Prohibitive

Rivaroxaban Added to Dual Antiplatelet Therapy Cuts Stent Thrombosis in ACS Patients

Zilver PTX 2-Year Results Published: Superior Safety, Efficacy vs. Angioplasty Sustained

Resultado de 2 Años del Zilver PTX Publicados: Seguridad y Eficacia Superiores frente a Angioplastia Sostenida

Conversations in Cardiology: Brief Question re: BMS-DES and DAPT

Aspirin Alone Just as Good as Dual Antiplatelet Therapy Beyond 12 Months

DAPT + Oral Anticoagulation: Indications and Risk Amelioration

Medtronic Approved to Update Resolute Integrity Stent’s ‘CE’ Mark Labeling on Dual Antiplatelet Therapy

Ideal Duration of Dual Antiplatelet Therapy May Depend on Stent Type

TCTMD’s Top 10 Most Popular News Stories for 2012

Case Report: Use of OrbusNeich’s Genous™ Stent with Bivalirudin for Acute Coronary Syndrome Patients at Risk for Bleeding Due to Hematological Cancer

CID Spa releases the NEXT Study 24-months data on its Cre8™ DES at TCT 2012

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content